News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AnGes MG Inc. And Seikagaku To Dissolve Joint Development Agreement For NFkB Decoy-Oligo-Based Intraarticular Injection


2/6/2006 10:35:26 AM

Tokyo, Feb 6, 2006 (JCN) - AnGes MG and Seikagaku jointly announced on February 3 that they have agreed to dissolve their agreement on joint development of NF-kappa B decoy oligodeoxynucleotide (NFkB decoy-oligo).

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES